Serum HBV pgRNA as a clinical marker for cccDNA activity Katja Giersch, Lena Allweiss, Tassilo Volz, Maura Dandri, Marc Lütgehetmann  Journal of Hepatology  Volume 66, Issue 2, Pages 460-462 (February 2017) DOI: 10.1016/j.jhep.2016.09.028 Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Serum HBV pgRNA as a clinical marker for cccDNA activity. (A and B) Serum HBV DNA (grey) and HBV pgRNA (black) levels in humanized mice before (baseline) and after treatment with NUCs (A, n=5) or PegIFNα (B, n=4) for 4–6weeks. Each mouse is depicted with total median and range. Every symbol represents one mouse. (C) Correlation of serum pgRNA and intrahepatic pgRNA relative to human GAPDH in HBV-infected mice untreated (n=23, black dots) and treated with NUCs (n=5, white dots) or PegIFNα (n=10, grey dots). Black line: Spearman r=0.82, p<0.0001. (D) Correlation of serum pgRNA and intrahepatic cccDNA/human cell in HBV-infected mice untreated (n=23, black dots and black solid line; spearman r=0.89, p<0.0001) or treated with PegIFNα for 2–6weeks (n=10, grey dots and grey line; spearman r=0.13, p=0.7330). Journal of Hepatology 2017 66, 460-462DOI: (10.1016/j.jhep.2016.09.028) Copyright © 2016 European Association for the Study of the Liver Terms and Conditions